Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 8:46 AM ET


Company Overview of Endocyte, Inc.

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical develop...

3000 Kent Avenue

Suite A1-100

West Lafayette, IN 47906

United States

Founded in 1995

81 Employees





Key Executives for Endocyte, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $475.6K
Co-Founder, Chief Scientific Officer and Director
Age: 67
Total Annual Compensation: $208.7K
Chief Financial Officer and Chief Operating Officer
Age: 49
Total Annual Compensation: $323.0K
Vice President of Research & Development
Age: 49
Total Annual Compensation: $278.5K
Vice President of Clinical Operations
Age: 58
Total Annual Compensation: $261.8K
Compensation as of Fiscal Year 2014.

Endocyte, Inc. Key Developments

Endocyte, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2015

Endocyte, Inc. announced unaudited financial results for the third quarter and nine months Ended September 30, 2015. For the quarter, the company reported collaboration revenue of $33,000 against $3,904,000 a year ago. Loss from operations was $10,325,000 against $5,778,000 a year ago. Net loss was $10,002,000 or $0.24 per share basic and diluted against $5,675,000 or $0.14 per share basic and diluted a year ago. For the nine months, the company reported collaboration revenue of $58,000 against $70,341,000 a year ago. Loss from operations was $32,072,000 against income from operations of $13,213,000 a year ago. Net loss was $31,476,000 or $0.75 per share basic and diluted against net income of $13,540,000 or $0.33 per diluted share a year ago.

Endocyte, Inc., Q3 2015 Earnings Call, Nov 03, 2015

Endocyte, Inc., Q3 2015 Earnings Call, Nov 03, 2015

Endocyte to Present Data on EC1456 at the European Cancer Congress 2015

Endocyte, Inc. announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will be presented at the European Cancer Congress 2015, being held Sept. 25 - 29, 2015, in Vienna, Austria. EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors.

Similar Private Companies By Industry

Company Name Region
Panoptic Targeted Science, LLC United States
LBB Industries, Inc. United States
Epigenetx, LLC United States
Miralus International Inc. United States
Ariston Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Endocyte, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at